Results 1 to 10 of about 3,193,961 (325)

Antifungal Resistance in Cryptococcal Infections [PDF]

Pathogens
Antifungal therapy, especially with the azoles, could promote the incidence of less susceptible isolates of Cryptococcus neoformans and C. gattii species complexes (SC), mostly in developing countries. Given that these species affect mostly the immunocompromised host, the infections are severe and difficult to treat.
Marcia S. C. Melhem, Diniz Pereira Leite Júnior, Juliana P. F. Takahashi, Milena Bronze Macioni, Lidiane de Oliveira, Lisandra Siufi de Araújo, Wellington S. Fava, Lucas X. Bonfietti, Anamaria M. M. Paniago, James Venturini, Ana Espinel-Ingroff   +10 more
europepmc   +5 more sources

Potential Strategies to Control the Risk of Antifungal Resistance in Humans: A Comprehensive Review

Antibiotics, 2023
Fungal infections are becoming one of the main causes of morbidity and mortality in people with weakened immune systems. Mycoses are becoming more common, despite greater knowledge and better treatment methods, due to the regular emergence of resistance ...
Ali A. Rabaan, Tarek Sulaiman, Shamsah H. Al-Ahmed, Zainab A. Buhaliqah, Ali A. Buhaliqah, Buthina AlYuosof, Mubarak Alfaresi, Mona A. Al Fares, Sara Alwarthan, Mohammed S. Alkathlan, Reem S. Almaghrabi, Abdulmonem A. Abuzaid, Jaffar A. Altowaileb, Maha Al Ibrahim, Eman M. AlSalman, Fatimah Alsalman, Mohammad Alghounaim, Ahmed S. Bueid, Awad Al-Omari, Ranjan K. Mohapatra   +19 more
doaj   +2 more sources

Antifungal resistance in dermatology

Indian Journal of Dermatology, 2018
Cutaneous fungal infections affect more than one-fourth of world's population. The pathogenesis and severity of fungal infection depend on various immunological and nonimmunological factors.
Varadraj Pai, Ajantha Ganavalli, Naveen Narayanshetty Kikkeri   +2 more
doaj   +3 more sources

Antifungal resistance, combinations and pipeline: oh my! [PDF]

Drugs in Context, 2023
Invasive fungal infections are a strong contributor to healthcare costs, morbidity and mortality, especially amongst hospitalized patients. Historically, Candida was responsible for approximately 15% of all nosocomial bloodstream infections.
Kayla R Stover, Brandon K Hawkins, J Myles Keck, Katie E Barber, David A Cretella   +4 more
doaj   +2 more sources

Antifungals and Drug Resistance

Encyclopedia, 2022
Antifungal drugs prevent topical or invasive fungal infections (mycoses) either by stopping growth of fungi (termed fungistatic) or by killing the fungal cells (termed fungicidal).
Chowdhury Mobaswar Hossain, Lisa Kathleen Ryan, Meeta Gera, Sabyasachi Choudhuri, Nazmun Lyle, Kazi Asraf Ali, Gill Diamond   +6 more
doaj   +2 more sources

Unveiling genome plasticity as a mechanism of non-antifungal-induced antifungal resistance in Cryptococcus neoformans [PDF]

Frontiers in Microbiology
Cryptococcus neoformans, a critical priority pathogen designated by the World Health Organization, poses significant therapeutic challenges due to the limited availability of treatment options.
Lijun Zheng, Yi Xu, Liangsheng Guo
doaj   +2 more sources

Candida Species Biofilms’ Antifungal Resistance [PDF]

Journal of Fungi, 2017
Candida infections (candidiasis) are the most prevalent opportunistic fungal infection on humans and, as such, a major public health problem. In recent decades, candidiasis has been associated to Candida species other than Candida albicans.
Sónia Silva, Célia F. Rodrigues, Daniela Araújo, Maria Elisa Rodrigues, Mariana Henriques   +4 more
doaj   +5 more sources

Epigenetic Regulation of Antifungal Drug Resistance

Journal of Fungi, 2022
In medical mycology, epigenetic mechanisms are emerging as key regulators of multiple aspects of fungal biology ranging from development, phenotypic and morphological plasticity to antifungal drug resistance.
Sandip Patra, Mayur Raney, Aditi Pareek, Rupinder Kaur   +3 more
doaj   +3 more sources

Fungal Drug Response and Antimicrobial Resistance

Journal of Fungi, 2023
Antifungal resistance is a growing concern as it poses a significant threat to public health. Fungal infections are a significant cause of morbidity and mortality, especially in immunocompromised individuals.
Paloma Osset-Trénor, Amparo Pascual-Ahuir, Markus Proft   +2 more
doaj   +1 more source

Antifungal Use and Resistance in a Lower–Middle-Income Country: The Case of Lebanon

Antibiotics, 2023
Antimicrobial resistance is a serious threat, particularly in low- and middle-income countries (LMICs). Antifungal resistance is often underestimated in both healthcare and non-clinical settings.
Nesrine Hassoun, Issmat I. Kassem, Monzer Hamze, Jad El Tom, Nicolas Papon, Marwan Osman   +5 more
doaj   +1 more source